Assessment Of Menopausal Symptoms And A I Iitude, And Intervention Study On Knowledge Of Hormone Replacement Therapy Among Peri Menopausal Women Seen At Outpatient Department (Krk)&Obstetrics And Gynaecology Clinic (O&G), Husm. by Nik Kazim, Nik Harlina Roza
ASSESSMENT OF MENOPAUSAL SYMPTOMS 
AND A I IITUDE, AND INTERVENTION 
STUDY ON KNOWLEDGE OF HORMONE 
REPLACEMENT THERAPY AMONG PERI 
MENOPAUSAL WOMEN SEEN AT 
OUTPATIENT DEPARTMENT (KRK) & 
OBSTETRICS AND GYNAECOLOGY CLINIC 
(O&G), HUSM. 
U'NIVERSITI SAINiS MALAYSIA 
NOVEMBER 2001 
BY: 
DR NIK HARLINA, .ROZA BT HJ. NIK KAZIM 
, , t ~ \ . 
DISSERTA TION SUBMITIED IN PARTIAl. 
FULFILMENT Of THE REQUIREMENTS fOR 
THE DEGREE Of MASTER OF MEDICINE 
(FAMILY MEDICINE) 
Acknowledgement 
Abbreviations 
Abstract 
Bahasa Malaysia 
English 
Contents 
Chapter One: Introduction 
1.1 General Introduction 
1.2 Literature Review 
Chapter Two: Objectives 
2.1 General objective 
2.2 Specific Objective 
2.3 Research hypothesis 
Chapter Three: Methodology 
3.1 Study design 
3.2 Study location 
3.3 Health service in Kelantan 
3.4 The study sample 
3.5 The questionnaire 
3.6 The Intervention 
page 
ii 
iv 
VI 
IX 
1 
6 
41 
42 
42 
43 
43 
43 
44 
46 
47 
4.5.2 Percentage response towards attitude 
4.6 Practice 
4.6.1 Factors influence not to use HRT 
4.6.2 Factors influence to use HRT 
Chapter Five: Discussions 
Chapter Six: Conclusions 
Chapter Seven: Limitations 
Chapter Eight: Recommendations 
Chapter Nine: References 
Chapter Ten: Appendices 
10.1 Malay questionnaire 
10.2 English questionnaire 
page 
72 
74 
75 
77 
90 
91 
93 
94 
105 
114 
ACKNOWLEDGEMENT 
I wish to express my sincere thanks and appreciation to both of my 
supervisors: 
i) Dr Shaiful Bahari Hj Ismail, Head of Family Medicine Unit, USM. 
ii) Dr Nor Aliza Abdul Ghaffar , Lecturer in Obstetrics and Gynaecology, 
Department of Obstetrics & Gynaecology, USM. 
iii) Dr Nik Hazlina Nik Hussain, Lecturer in Obstetrics and Gynaecology, 
Department of Obstetrics & Gynaecology, USM. 
for their excellent guidance, overall comments and criticisms of the study. 
My courteous thanks to all lecturers in Family Medicine Unit, Dr Amaluddin 
Ahmad, Dr Juwita Shaaban and Dr Sheikh Mohd Amin s. Mubarak for their 
general advice. 
My special appreciation to Family Medicine Specialist at Klinik Kesihatan 
Kuala Besut, Dr Sukarno Mohd Saud, for his understanding and support given 
through out the preparation of this dissertation. 
11 
I also wish to thank Dr Rosli Abdullah for allowi ng me to conduct the study 
at Klinik Rawatan Keluarga (KRK). My sincere thanks to Sister Norhimah and 
all the staffs in Klinik Rawatan Keluarga for their tremendous support for 
the success of this project. 
Thank you also to those who have been involved either directly or indirectly 
in the project. 
Last but not least, my deepest regards to my family, both my parents and 
especially to my beloved husband, Major (Dr) Mazdy Haji Ismail for his 
patience, encouragement and understanding that make this study a success 
and worth while. 
III 
ABBREVIATIONS 
AD Alzheimer's Disease 
BMD Bone mi neral density 
BMU Basi c multi cellular units 
CAD Coronary artery disease 
CEE Conjugated equine estrogen 
CVD Cardiovascular disease 
ECG Electrocardiograph 
ERT Estrogen replacement therapy 
fSH Follicle stimulating hormone 
HDL High density lipoprotein 
HKB Hospital Kota Bharu 
HRT Hormone replacement therapy 
HUSM Hospital Universiti Sains Malaysia 
rHD Ischaemic Heart Disease 
KAP Knowledge, Attitude and Practice 
KRK Klinik Rawatan Keluarga 
LDL Low density lipoprotein 
LH Luteinising hormone 
IV 
O&G Obstetrics and Gynaecology 
OPD Outpatient department 
SERMs Selective estrogen receptor modulator 
SPSS Statistical Package for Social Sciences 
TG Triglyceride 
UTI Urinary tract infection 
WHI Women's Health Initiative 
WHO World Health Organization 
WHS Women's Health Study 
v 
ABST CT 
BAHASA MALAYSIA 
OBJEKTIF: 
Kajian ini adalah untuk memeriksa sikap dan pengetahuan pengguna tentang 
terapi penggantian harmon (TPH), mengenai alam putus haid, gejala putus 
haid, penggunaan TPH, dan juga membandingkan tahap pengetahuan asas 
sebelum dan selepas program intervensi kaunseling secara individu diberikan. 
METHODA: 
Di dalam kajian ini soalan yang telah dilengkapkan oleh 55 pengguna TPH 
daripada klinik menopos, HUSM dan 54 pesakit (bukan penggunaTPH) 
daripada Klinik Pesakit Luar, HUSM sebagai kontrol. Kajian ke atas dua 
kumpulan ini dijalankan serentak mulai lhb Jun hingga 31 Disember 2000. 
Terdapat 40 soalan yang mana ianya diterjemahkan dan ditambah daripada 
soalan-soalan yang digunakan dalam kajian-kajian di London dan Scotland 
untuk disesuaikan dengan masyarakat tempatan. Soalan-soalan terdiri 
daripada gejala-gejala putus haid, pengetahuan dan sikap mengenai TPH. 
Soalan yang sarna diberikan kepada bukan pengguna TPH. Intervensi 
kaunseling secara individu dilakukan kepada bukan pengguna mengenai atam 
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putus haid dan TPH. Lima belas soalan pengetahuan yang sama diberikan 
selepas lapan minggu sesi kaunseling. Pengetahuan asas yang dikaji seterusnya 
diberi markah dan tahap pengetahuan tersebut dinilaikan menggunakan skala 
Likert. Data yang diperolehi kemudiannya dianalisa menggunakan Statistical 
Package for Social Sciences (SPSS). 
KEPUTUSAN: 
Keputusan kajian menunjukkan tiada perbezaan antara umur, bangsa, taraf 
perkahwinan, pendapatan dan status penyakit. Tetapi terdapat perbezaan di 
antara pekerjaan dan taraf pendidikan di antara dua kumpulan tersebut. 
Kesan -kesan putus haid terutamanya kesan \\ klasikal/vasomotor" adalah yang 
paling dirasai. Walaupun di kalangan wanita tersebut mempunyai keseluruhan 
gejala putus haid, mereka tidak tampil meminta bantuan. Ini disebabkan oleh 
beberapa faktor iaitu kekurangan pengetahuan tentang TPH, mempunyai 
sikap yang negatif tentang alam putus haid dan TPH dan mereka adalah dari 
9010n9an yang kurang berpengetahuan. Dibandingkan pengetahuan pengguna 
dengan bukan pengguna, purata markah ialah 7.78 dan 5.07. Perbezaan 
purata markah di antara pengguna dan bukan pengguna TPH adalah signifikan. 
Keputusan juga menunjukkan perbezaan purata markah sebelum dan selepas 
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intervensi dimana purata markah sebelum dan selepas intervensi ialah 5.07 
dan 10.26. Perbezaan purata sebelum dan selepas intervensi di antara kedua-
dua kumpulan secara statistiknya adalah signifikan (p<0.05). 
KESIMPULAN: 
Pengetahuan secara keseluruhannya di antara pengguna TPH dan bukan 
pengguna TPH tidak memuaskan dan sikap bukan pengguna adalah negatif 
berbanding dengan pengguna TPH. Kebanyakan daripada mereka masih belum 
sedar tentang wUjudnya TPH dan sekiranya mereka sedar, tahap pengetahuan 
yang salah adalah tinggi. 
Kajian ini menunjukkan bahawa intervensi kaunseling secara individu telah 
meningkatkan pengetahuan mengenai TPH. Oleh itu, adalah tanggungjawab 
bersama pengamal perubatan untuk memberitahu dan menasihati wanita-
wanita yang berdiam diri dan merana membakar diri. 
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ENGLISH 
OBJECTIVES: 
This study was designed to examine HRT users' attitudes and knowledge of 
menopause and HRT, their menopausal symptoms, comparing that with a 
control group (non HRT user) and to examine the effectiveness of counseling 
intervention in educating the non HRT user. 
METHODS: 
In this survey, a self administered questionnaire was completed by 55 
patients of HRT users, taken from menopause clinic, HUSM and by 54 
patients from outpatient department (OPD), HUSM as a control group (non 
HRT user). The study was started simultaneously in both groups in year 
2000 from June, 1st to December 31st. The questionnaire consisted of forty 
questions which had been used in three surveys in London and Scotland 
tested on menopause symptoms, knowledge and attitude. Control patients 
were given a similar questionnaire. A counseling intervention was carried out 
in the control group (non HRT user), tuning towards menopause and HRT. A 
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similar fifteen questions on the knowledge aspects were tested post 
counseling. The knowledge studied were then scored based on Likert scale. 
The questions were modified, simplified, translated and new questions are 
added in order to suit our local population. All the data were analysed using 
Statistical Package For Social Sciences (SPSS). 
RESULTS: 
The results showed no significant difference between the two groups with 
respect to age of respondents, ethnicity, marital status, income and medical 
status. However there was a significant difference in the level of education 
and occupation between the two groups. The menopausal symptoms especially 
the classical/vasomotor symptoms are Widely experienced in both groups. 
The reason why these women do not use HRT are due to several confounding 
factors. They are unaware of HRT and were let down by poor level of 
education with negative attitudes towards menopause and HRT. Comparing 
the basic knowledge of menopause and HRT from both groups, they have 
poor basic knowledge (mean score of 7.78 in HRT user and 5.07 in non HRT 
user). The mean difference between the HRT user and non HRT user was 
significant. There was also a marked difference in the mean knowledge score 
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post-intervention programme in non user group. The mean score pre 
intervention is 5.07 as compared to 10.26 post intervention. The difference 
of means before and after intervention between the two is again 
statistically significant, p <0.05. 
CONCLUSIONS: 
In conclusion, the overall knowledge of HRT users and non HRT users were 
poor and attitudes towards HRT were more negative among non users. Many 
of them are still not aware of the existence of HRT, but even if they do, 
misconceptions are still high. 
This study showed that intervention by counseling improves the knowledge 
of menopause in the non user group, hence leads these women to make 
informed decisions to use HRT. Therefore, there was a need for health care 
providers to make an effort to inform and offer HRT to these women who 
are sufferi n9 in si lence. 
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INTRODUCTION 
1.1 GENERAL INTRODUCTION 
The menopause, which is the last menstrual period marks the end of the 
reproductive life in a woman. It is a landmark and is one of the few 
certainties in women's life. However this does not signal the end of the 
sexual and social activities. 
In a study on the menopausal situation in MalaYSia, the mean age of 
menopause was found to be 50.7 years (Nik Nasri , 1994). In a previous 
study several years ago, the mean age was 48.7 years (Hamid Arshat et al 
1989). Both are within the range documented in most industrialized 
societies. A menopause which is a biological phenomenon, was not talked 
much before in MalaYSia but is more frequently discussed now. The reason is 
due to better information available and more importantly it is attributed to 
the fact that the average life expectancy of the MalaYSian women is 
increased, from 68 years in 1985 to 74 years in 1993 (Vital Statistics -
Malaysia 1995) i.e women are spending one third of their lives in the post 
menopausal period, in a state of oestrogen deficiency. 
Apart from the long recogni zed problems, vasomotor i nstabi lity, uro-genital 
and psychological problem, there is also a concomitant and slow pathological 
deterioration in many other major organ systems. Osteoporosis, 
cardiovascular disease and Alzheimer's disease are all being increasingly 
linked to oestrogen deficiency and with growing awareness, more links are 
being established. 
Menopause has led to the prescription of sex steroid hormones to replace 
the declining levels of natural sex steroid hormones from the "ageing 
ovaries" of these peri menopausal women (Datuk Sinnathuray, 1989). 
The widespread beneficial effects of HRT in improving the health related 
quality of life of peri menopausal women are well documented. Unfortunately, 
despite all the beneficial effects, most women do not begin to use these 
exogenously administered sex steroid, or they may discontinued the use of 
these agents prematurely. Consequently the full benefits of the therapy will 
not be achieved. 
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Survey and audits of menopause and HRT has identified deficiencies. A 
population based survey on menopausal symptoms concluded that majority of 
them experienced the menopausal symptoms especially the classical 
symptoms but less percentage defined it as problematic. However a 
combination of classic, somatic and psychological symptoms might constitute 
a considerable problem (Maureen P et aI1996). 
In terms of experiencing the menopausal symptoms, the Israelian women 
look upon menopause as normal, natural part of their lives in which it makes 
less likely to use HRT. Majority, 83.5cro knew about HRT but only 6cro use 
HRT (Blumberg et al 1996). This is in contrast to a survey done in Glasgow in 
1989. With reference to their experience of the menopause, they stated 
that 50cro expressed a need of treatment (Barlow et al 1989). 
A population based survey in Grampian region of Scotland identified only 10"0 
was on treatment. Majority of them did not consider treatment because 
aocro had never discussed with a doctor. The reason for low number of HRT 
users is not due to attitude among them (Hazel K et al 1993). A local study 
done by Nazimah Idris et ai, 1996 illustrated that awareness of HRT 
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existence is very disappointing, the knowledge about benefits is 
unsatisfactory and misconception among study population is sti II high. 
Despite the poor knowledge, Kristi J Ferguson concluded that positive 
effect regarding HRT use made by the physician, by simple communication 
between a women and her physician could significantly alter HRT use 
(Ferguson K 1989). 
In 1991, the special Menopause clinic was set up in Malaysia through family 
planning clinic. Various forms of HRT are available - oral tablets, skin 
patches, gel, cream and implant. According to the patient's wishes, HRT is 
tailored to be cyclical with regular withdrawal bleeding or continuous with no 
withdrawal bleeding. 
The service for menopause women are available at primary care level, under 
the care of family physician at present. Primary care physicians are to be 
responsible for initial recognition and management of these patients. HRT 
represents one of the most significant advances in preventive medicine in 
this century and may be used safely by most women provided they do so 
under medical supervision. 
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To properly implement HRT among the peri menopausal women who would 
benefit most, we have to go to the source, the women themselves. We 
wanted to assess how women feel about menopause in general, whether they 
think it as a deficiency disease. We also wanted to assess about HRT and its 
benefit. Therefore this study will assess the menopause symptoms among 
peri menopausal women with the objectives to determine the level of 
knowledge, attitude, practice and misconception among study population and 
to evaluate the influence of counseling of these women. 
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1.2 LITERATURE REVIEW 
Definition of menopause 
The term menopause is derived from the Greek words for month and end, 
and refers to the cessation of menstrual periods. Menopause which is the 
last menstrual period marks the end of the reproductive life in a woman. The 
premenopause period begins several years before any signs of climacteric 
occur. It usually begins at about 40 and its end is determined by the 
menopause. The transitional period towards the menopause has two phases, 
the climacteric and the peri menopause. The climacteric usually begins around 
the age of 45 years, and according to the definition of Senium, ends at the 
age of 65. Peri menopause also begins with the onset of the climacteric 
symptoms. It is a period of time around the menopause and ends one year 
after the menopause. While the postmenopause period usually refers to the 
period at least 1-2 years after the menopause ( Jaszmann 1976 ) -
refer Figure 1. 
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Figure 1 The climacteric period (Jaszmann LJB) 
Evidence to support the idea that the climacteric, which by definition is 
transition period from reproductive to non reproductive, is an 
endocrinopathy, is based on the demonstration of four classic sequential 
steps. First there must be morphologic changes in the ovary, an endocrine 
gland. Second, an alteration in the endocrine mileau must occur, that 
changes in sex hormone concentrations are measurable. Third, changes in 
estrogen receptor target tissue must be evident and finally women must 
seek medical help with complaint preceeding changes in ovaries, sex steroid 
hormone and target tissue responses (Ann M Voda 1992). 
The myth of menopause as an estrogen deficiency disease was first proposed 
by Robert Wilson, a New York Gynaecologist in 1960s. Wilson believed that a 
woman's destiny after menopause without estrogen replacement was to 
spend that period of live in living decay. Therefore in the 1970's estrogen 
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hormone primarily estrone was used in treating the menopausal symptoms. 
Besides the beneficial effects of estrogen for treating menopausal 
symptoms, Wilson also proclaimed that the hormone would protect against 
osteoporosis, heart disease, and cancer of breast and uterus (Wilson R 
1963). In his book, Feminine Forever, a compelling word of picture was 
painted by Wilson about the horrors of living through the post menopausal 
years in a body without estrogen (Wilson R 1966). After the widespread 
publicity that estrogen caused rather than prevented uterine cancer, 
treatment of menopause women diminished, decrease to 40 'Yo. A concerted 
effort to rehabilitate estrogen therapy was undertaken. A major step 
toward rehabilitation resulted when progestin was added to the estrogen to 
minimize the treatment of menstrual cycle and to transform the rapidly 
proliferating uterine endometrium into a secretory organ (Ann M Voda 1992). 
There was a major difference between Wilson's and Uttian's definition of 
menopause. While Wilson's described it as a deficiency disorder, Uttian's 
definition of climacteric was constructed to represent a subset of 
menopausal women whom the changes were viewed as outside of context of 
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normality. Therefore, Uttian argued some form of hormone replacement in 
appropriately selected women only (Uttian WH 1987). 
Physiology of menopause 
At the time of menopause, a shift to a state of hypoestrogenecity 
accelerates. The ovaries of women become depleted of oocytes as well as 
their complementary granulose cells, the estrogen progestogen producing 
cells of ovary. 
Ovulation occurs less frequently prior to the menopause and the Graafian 
follicles become increasingly insensitive to gonadotrophin stimulation. 
Inadequate follicular maturation leads to low estrogen production and 
eventually, cessation of menstruation. 
After menopause, much of the major source of estrogen, primarily estrone, 
are derived from the aromatization of androstenedione in body fat, the 
amount of aromatization of androstenedione to estrone and testosterone to 
estradiol more than doubles in postmenopausal women and relates directly to 
the amount of body fat (Gupta & Kenney 1997). 
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The biochemical diagnosis of menopause rests on an elevated serum follicle 
stimulating hormone (FSH) of greater than 40 IU/I and low estrogen levels 
of less than 80 pmoi/i. FSH and LH (Iuteinising hormone) levels rise steadily 
during the first 12 months after menopause and then they either level off or 
decrease. The stromata of the ovaries continue to produce androgens 
throughout life. 
Although the depletion of estrogen and progesterone producing cells is a 
gradual 40 to 50-year long process, the last menstrual period can be abrupt 
in a small percentage of women. In most women, however the menopause is 
preceeded by irregular or oligomenorrheic menstrual cycles. The last two 
years before natural menopause may consequently be associated with the 
symptoms of menopause or climacteric. This peri menopausal interval prior to 
menopause can be a time of rising FSH levels, rising and falling estradiol 
levels and vasomotor symptoms (Morton & Hall - Health Care for Older 
Women). 
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Age at menopause 
According to historic literature, the average age of menopause has not 
changed for the last 2000 years. In industrialized countries, menopause 
usually occurs between the age of 45 to 55 years with the median age at 51 
years (Brambilla & McKinlay 1989). In a study on the menopausal situation in 
Malaysia, the mean age of menopause was found to be 50.7 years (Nik Nasri, 
1994). However in the earlier study by Hamid Arshat, the overall average 
age of menopause was slightly lowered, reported at 48.7 years (Hamid 
Arshat 1989). Both of the ages in the study fall within the range 
documented in industrialized societies. 
Serum oestrogen concentrations have a pronounced impact on the estimation 
of age in peri menopause period (Ludwig et al 1999). The age of onset is 
however by far and large an individual experience. 
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Factors influencing age of onset 
The Massachusetts Women's Health Study (Sonja McKinlay et a11985), large 
scale prospective trial conducted in the United States, found that cigarette 
smoking was the only factor among those examined that affected age of 
menopause, producing a shift of 1.5 years. There appears to be a dose 
related trend, where women who smoke greater number of cigarettes for 
longer periods are more likely to experience the greatest reduction in age at 
menopause. Even women who have stopped smoking are still likely to undergo 
menopause at an earlier age than their counterparts who never smoked. 
Socioeconomic status, marital status, age at marriage, number of 
pregnancies, body height and racial heritage were the other factors 
investigated in this study. These were not found to have any clear 
correlation with the age of the menopause. 
The mechanisms by which cigarette smoking affect hormonal changes is not 
fully understood. Smoking accelerates the hepatic metabolism of oestrogens 
and decrease the bioavailability of oestrogen (Sonja McKinlay et aI1985). 
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Menopause symptoms 
The climacteric women faces a variety of clinical problems that are thought 
to be associated with the decline in estrogen production and function that 
follows menopause. These include vasomotor symptoms, genitourinary 
symptoms, physical symptoms and as well as psychological symptoms. 
Cultural influences, biologic variability among different races, psychological 
factors and sociologic factors all can have an enormous impact on the 
meaning, experience and symptomatology of menopause (McNagny, 1999). 
Vasomotor symptoms 
Vasomotor symptoms are the predominant symptoms and most characteristic 
manifestations of climacteric and menopause. The symptoms include 
hotflush, night sweat and palpitation. The vasomotor symptoms of menopause 
appear attributable to a dysfunction of the brain's thermoregulatory center 
in the hypothalamus, with a sudden downward setting of the hypothalamic 
thermostat. The physiological changes that accompany this menopausal 
central thermal dysfunction include an acute rise in skin temperature, 
peripheral vasodilatation, a transient increase in heart rate, fluctuations in 
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the electrocardiograph (ECG) baseline, and a pronounced clearance in skin 
resistance (5turdee et aI1978). 
The physiological changes of sweating and vasoconstriction result from 
different peripheral sympathetic function; sympathetic cholinergic fibers 
excite sweat glands, while tonic alpha adrenergic neurons control peripheral 
vasoconstriction. Both of these responses lower core temperature during hot 
flush (Mulley G et al 1997). 
The hot flushes have been known for several milleania, described first in 
ancient Egypt. Hot flushes are described as transient periods of intense 
sensation, flushing, profuse sweating primarily on the chest, neck and head 
(Kronenberg & Downey 1987). 
For most of these women, hot flush means an occasional sensation of warmth 
and discomfort, others 10 - 15<ro experience hourly waves of heat sensation 
and drenching sweats that disrupt daily activities and wreak havoc on sleep. 
Hot flushes generally subside spontaneously within about a year, however 
this can persist for 10, 20 or even 40 years (Kronenberg 1990). These 
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episodes can be physically and emotionally draining and can seriously 
interfere with work, family and social relationship. 
Urogenital symptoms 
The urogenital tissues are embryonically same and are estrogen dependant. 
Declining estrogen levels lead to atrophy of the urogenital tissues and 
vaginal thinning and shortening. Vaginal dryness and atrophy can result and 
lead to atrophic vaginitis, urethral irritation, dyspareunia in 20 - 30CYo of 
postmenopausal women. In addition urinary tract infection and urinary 
incontinence may develop because of tissue thinning, laxity, decreased 
urethral apposition and alteration of vaginal flora (Toni M Cutson 2000). 
Most of these changes can be treated with estrogen replacement therapy 
(ERn. With ERT the vagina mucosa thickens, the pH of the vagina decreases 
and there is a decrease in vaginal dryness. ERT either delivered vaginally or 
orally has same efficacy. A dosage of O.3mg /day of conjugated equine 
estrogen (CEE) produces therapeutic result in women with vaginal mucosal 
atrophy, 0.1 to 0.2 mg of estradiol in vaginal cream is also effective (Toni M. 
Cutson 2000). 
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Similarly ERT has a beneficial effect on urinary tract. A meta-analysis of 
estrogen treatment ( oral or intravaginal) for urinary incontinence revealed 
a significant improvement in subjective symptoms but no improvement in 
objective measures such as urodynamic testing (Font et aI1996). 
Psychological symptoms 
It is during the declining estrogen level that susceptible women begin to 
have problems related to insomnia, irritability and mood disturbances. 
Vasomotor symptoms tend to occur with the onset of rapid eye movement 
sleep, thus disrupting normal sleep architecture. These women may also 
report difficulty not only in falling asleep but also maintaining sleep as well 
as early morning awakening. This resulted in daytime fatigue, poor 
concentration and dysphoria which may be difficult to differentiate from 
the somatic symptoms associated with depression (Toni M Cutson 2000). 
Insomnia has been shown to be estrogen dependant, however brain 
mechanisms remain unclear. Estrogens seem to have direct effect on sleep 
regularity areas of the hypothalamus, preoptical area and hippocampus 
(Halbreich 1997). Estrogen therapy however improves mood and dysphoria, 
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possibly by affecting the metabolism of serotonin in the central nervous 
system or due to indirect effect of improved sleep mechanism (Sherwin 
1996). 
Reports are inconsistent about association between menopause and 
depressed mood. Studies from clinic based endorse depression as part of 
the menopause, community based populations do not. It appears that women 
are more tolerant of the physical changes associated with menopause but 
seek care for mood symptoms. Like other community based studies, the 
Massachusette Women Health Study conducted by Avis did not show an 
increase in depression associated with menopause (Avis et aI1997). 
EFFECTS OF MENOPAUSE 
A) Menopause and Cardiovascular Disease 
Cardiovascular disease kills 500,000 American women each year making it 
the leading cause of death in women in the US (American Heart Association 
1997). It is responsible for more female deaths than all other diseases 
combined. The picture is similar in other developed countries and in many 
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developing countries. In Malaysia, 29CYo of female deaths are directly 
attributable to cardiovascular disease (Vital Statistic Malaysia 1995). 
There are clear differences in the pattern of disease between men and 
women. Men have 3.5 times the lifetime risk of developing coronary heart 
disease (CHD) (Prashat et aI1999). The Framingham study demonstrates age 
specific differences :The female Imale risk ratio for CHD is 1:7 in the third 
decade of life and increases progressively to reach parity only after the 
seventh decade. This escalation of risk is pronounced after the menopause: a 
recent estimate suggests a threefold rise in risk is directly attributable to 
the menopause (Kannel et al 1976). Despite the disappearance of gender 
differences after the menopause, overall, women are protected from 
coronary heart disease. They lag behind men in the incidence of CHD by 10 
years and of myocardial infarction by 20 years (Kannel et al 1976). CHD 
alone accounts for 40CYo of the difference in mortality between the sexes. 
A complex interplay of factors leads to the development of postmenopausal 
cardiovascular disease. While many of these, such as genetic predisposition, 
cigarette smoking, dyslipidaemia, hypertension and diabetes for both sexes, 
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women have to contend with the profound effects of oestrogen withdrawal 
(The Writing Group for the PEPI Trial 1995). Indirect evidence of the 
effects of this hypo-oestrogenaemia comes from prospective studies. The 
1991 Nurses Health Study report assessed 48,470 postmenopausal women 
who did not have cardiovascular disease at baseline and followed this cohort 
for 10 years. There was a relative risk of 0.53 (95croCI 0.31 to 0.91) 
(Stampfer M et al 1991). Current oestrogen use was associated with both 
reduced incidence and mortality from CHD, independent of other risk 
factors. 
Dyslipidaemia contributes a major role in coronary heart disease. During 
their reproductive years, women have higher level of high density 
lipoprotein cholesterol (HDL) and lower level of low density lipoprotein (LDL) 
and total cholesterol levels than their male counterparts. The HDL continues 
to be higher even after menopause, although after age 70 it begins to 
equalize. Overall therefore, the menopause is associated with increased 
total cholesterol (5cro), LDL (llcro), and TG (scro) and decreased HDL (6cro) 
(Matthews 1989). 
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Epidemiological studies have confirmed the protective effect of HDL and 
established that among all the lipids, HDL level seems to be the most 
powerful predictor of CHD. The largest of these is the Framingham study 
which demonstrated a 40 - 50 eyo decrease in incidence for every 10 mg/dL 
(0.24 mmol/L) increase in HDL (Castelli 1992). 
In evaluating the impact of HRT in reducing cardiovascular disease, 
population studies show a consistent benefit. Meta - analysis of existing 
observational studies confirmed that the post menopausal oestrogen 
replacement reduces cardiovascular risk by as much as 40 - 50eyo (Grodstein 
F et aI1996). 
8) Osteoporosis 
Osteoporosis is defined as a systemic skeletal disease characterized by low 
bone mass and micro architectural deterioration of bone tissue leading to 
increased bone fragility and susceptibility to fracture (Consensus 
Development Conference 1993). The skeleton consists of discrete 
microscopic units called basic multicellular units (BMUs). BMUs have 
osteoclasts (bone resorbing cells) and osteoblasts (bone forming cells) along 
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with their respective precursors, for remodelling of the skeleton. The aim of 
remodeling being to maintain the integrity of the skeleton. 
The peak bone mass which is the maximum density of the bone is usually 
built by the age of 25-30 years. Bone loss occurs inevitably after this. 
Imbalance between the amount of bone resorbed and bone forming form the 
basis of age related and menopause related bone loss. Once a woman reaches 
about 40 years of age, resorption begins to exceed formation by about 0.5CYo 
per year. When menopause begins, the amount of bone being resorbed 
increases sharply, while the amount being formed increases moderately. 
Consequently, each year losses of lCYo to 3CYo of cortical bone and up to 5CYo of 
trabecular bone occur. The accelerated erosion of bone lasts about 10-15 
years, after which bone losses considerably diminished. Bone loss may 
actually stop after the eighth decade. 
Menopause-related bone loss results in a total of 15cro to 30cro decrease in 
trabecular bone and a 10cro to 15cro reduction in cortical bone. Therefore 
estrogen deficiency is responsible for one third to one half of the bone lost 
during a woman's lifetime (Ettinger B 1985). Hence, maintaining adequate 
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estrogen levels remains the most important way of maintaining adequate 
bone density in women (Ravn P et 011999). 
Estrogens have been shown to regulate different aspects of remodeling 
process. On the bone it exerts its action on the osteoblasts and osteoclasts. 
At the tissue the main action is to reduce bone turnover. For the benefit of 
these women, all women with decreased bone density should be offered 
estrogen replacement therapy (ERT) unless contraindications exist. 
Conjugated estrogens in dosages of 0.625 mg per day and transdermal 
estrogen ( a weekly patch containing 0.05 mg ) are equally effective in 
reducing bone loss in postmenopausal women (Lindsay R et aI1984). 
In relation to the type of HRT used, Cauley et al found that bone mineral 
density (BMD) was similar in women using unopposed estrogen or estrogen 
plus progestin (Cauley et al 1995). This is in contrast to The Postmenopausal 
Estrogen Progestogen Intervention Trial (PEPI Trial). The PEPI trial a 3 year 
longitudinal study, showed significant benefits of 0.625 mg of conjugated 
equine estradiol in the maintenance of bone density at the spine and the 
femoral neck. Constant compliance can produce a 5"0 and 2"0 increase in bone 
22 
mineral density (BMD) in the spine and the femoral neck, respectively. The 
addition of continuous progestin resulted in a significantly higher BMD than 
with cyclic therapy (The Writing Group For PEPI Trial 1996). 
The sooner estrogen is started after menopause the more protective effect 
on the bone. Studies have been made on the effect of the timing of 
initiation and duration of postmenopausal estrogen therapy on bone mineral 
density. Studies by Cauley J A et ai, 1995 and Schneider DL et ai, 1997 
concluded that current users who started ERT at menopause had the highest 
BMD levels, which were significantly higher than "never" users or "past" 
users who started at menopause and continued it for at least 10 years 
(Cauley et al1995 & Schneider et aI1997). 
Current users who started ERT within five years of menopause had a 
decreased risk of hip, wrist and all nonspinal fractures compared with those 
who never used estrogen. Cauley et al also found long term users who 
initiated therapy five years after menopause had no significant reduction in 
risk for all non spi nal fractures, despite an average duration of use of 16 
years (Cauley et al 1995). This is supported by the Rancho Bernando Study 
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that current users who started after 60 years and continued for nine years 
had the same BMD of 7 -19cro (Schneider et al 1997). Therefore early 
initiation of ERT with respect to menopause may be more important than the 
total duration of use. Estrogen initiated early in menopause and continued 
into late life appears to be associated with the highest bone density. 
As compared with HRT to antiresoptive therapies, bisphosphonates, 
calcitonin, Selective Estrogen Receptor Modulator (SERMs) - raloxifene, 
estrogen was found to be more superior in increasing BMD. This was shown in 
Lindsay study, alendronate increased spinal BMD by 3.5cro and 1.9cro at the 
spine and the hip, while the response to estrogen was 1-2% higher than this 
at both sites (Lindsay R et aI1998). A synergistic action has also been shown 
with alendronate in combination with estrogen replacement after one year of 
treatment from this study. When raloxifene was compared to estrogen, the 
latter proved to be slightly more efficient in long term in suppressing bone 
turnover (Heaney & Draper 1997). 
As bone loss in later life is inevitable, thus peak bone mass should be built up 
adequately in the first 20-30 years of one's life to cope with the loss that 
24 
